Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
93.07 USD | +0.16% | +1.34% | +0.76% |
01-22 | RBC Adjusts Price Target on Gilead Sciences to $84 From $83, Maintains Sector Perform Rating | MT |
01-22 | ALX Oncology Holdings Inc. Announces Chief Financial Officer Changes | CI |
1m. EPS revision | 1m. Revenue rev. | 4m. EPS revision | 4m. Revenue rev. | 1y. EPS revision | 1y. Revenue rev. | Divergence of Estimates | Nbr of analysts | ||
---|---|---|---|---|---|---|---|---|---|
26 | |||||||||
26 | |||||||||
22 | |||||||||
22 | |||||||||
27 | |||||||||
24 | |||||||||
19 | |||||||||
19 | |||||||||
20 | |||||||||
22 | |||||||||
26 | |||||||||
22 | |||||||||
21 | |||||||||
15 | |||||||||
19 | |||||||||
18 | |||||||||
17 | |||||||||
17 | |||||||||
16 | |||||||||
Average | 21 | ||||||||
Weighted average by Cap. | 23 |
- Stock Market
- Equities
- GILD Stock
- Sector Gilead Sciences, Inc.
- Sector revisions
MarketScreener is also available in this country: United States.
Switch edition